Lanreotide supply disruption may extend beyond H1 FY27
Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
high · management_commentaryCipla Ltd — Q3 FY26
Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D s...
bearish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
U.S. launch pipeline may face delays or competition
Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
high · analyst_questionElevated R&D spend may persist, pressuring margins
R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
medium · data_observationSemaglutide generic launch could impact tirzepatide uptake
Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive.
medium · analyst_question